ABSTRACT

Low triiodothyronine syndrome is a physiological adaptation encountered in anorexia nervosa (AN) and generally improves with sufficient weight gain. However, when a primary thyroid pathology accompanies AN, both the evaluation of thyroid hormone levels and the management of the co-morbid disease become more challenging. Hashimoto thyroiditis could complicate the management of AN by causing hyper- or hypothyroidism. AN could also negatively affect the treatment of Hashimoto thyroiditis by altering body weight and metabolic rate, as well as by causing drug non-compliance. We present the case of a 15-year-old boy with comorbid AN restrictive sub-type and Hashimoto thyroiditis. In this case report, we aimed to draw attention to the challenges that could be encountered in the diagnosis, treatment, and follow-up of patients with AN when accompanied by Hashimoto thyroiditis.

Keywords: Anorexia nervosa, Hashimoto thyroiditis, adolescent, hypothyroidism

Conflict of interest: None declared

Received: 04.08.2015
Accepted: 15.10.2015

Introduction

Anorexia nervosa (AN) is a psychiatric disorder with significant neuroendocrine consequences. In patients with eating disorders (EDs), the hypothalamic-pituitary-thyroid axis is possibly the most studied neuroendocrine pathway. Thyroid function tests of patients with AN resemble the sick euthyroid state which is characterized by low total triiodothyronine (T3) levels, usually normal thyroid-stimulating hormone (TSH) levels, and normal or slightly low thyroxin (T4) levels (1,2). This physiological adaptation state is also known as low T3 syndrome. Decreased deiodination of T4 to T3, increased peripheral conversion to reverse T3, and decreased thyroidal T3...
Body mass index was 17.55 kg/m² (<3rd percentile). His body weight gain, T₃ levels are expected to increase and to attain the normal range (5).

Hashimoto thyroiditis, which can lead to hypothyroidism and sometimes to hyperthyroidism, is a condition which needs to be considered in the differential diagnosis of AN. The laboratory and clinical resemblance of hypothyroidism and AN could complicate the diagnosis and management of both diseases, while a hyperthyroid state could deteriorate the psychological and physiological symptoms of AN.

In this case report, we present these challenges encountered in the diagnosis, treatment, and follow-up of a patient with AN restrictive sub-type accompanied by Hashimoto thyroiditis.

**Case Report**

We present a 15-year-old boy who was admitted to our hospital with significant weight loss, malaise, and cold intolerance. Written informed consent for presentation was obtained from the patient and his parents.

The patient weighed 102 kg until four years ago, at which time, with the help of a dietitian, he started to lose weight. However, after losing 2 kg, he discontinued the dietary regime. Two years later, when he weighed 100 kg, he decided to lose weight again because he felt uncomfortable with the way he looked and felt very overweight. Within a year, he lost 20 kg by eating less and playing basketball every day for approximately two hours a day. At that time, he had to quit basketball due to a busy school schedule which led to a fear of gaining weight, causing him to restrict his diet even more.

By restricting his daily intake to 500 kcal, he had lost 17.5 kg within the last two months before presenting to our clinic. The patient denied having body image problems but agreed that he had an intense fear of gaining weight. Past medical history was unremarkable except for an appendectomy performed when he was 7 years old. The family history revealed that two of his aunts have Hashimoto thyroiditis.

At admission, the patient’s body weight was 80.7 kg (50-75th percentile). Height was 186 cm (>97th percentile) and body mass index was 17.55 kg/m² (<3rd percentile). His body temperature was 36.1 °C and respiratory rate was 22/min. His supine blood pressure was 100/60 mmHg and heart rate was 40 bpm. His standing blood pressure was 95/60 mmHg and heart rate was 66 bpm. Cardiac examination was normal except for the bradycardia, and other systems were also normal on his physical examination. Meeting the diagnostic criteria of the fourth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM IV), he was diagnosed with AN-restrictive type and hospitalized due to bradycardia. His laboratory investigations which included complete blood count, liver and kidney function tests, glucose and electrolyte levels, sedimentation rate, cortisol, cholesterol levels, and urinary analysis were all within normal ranges. Thyroid function tests revealed very low TSH levels (0.025 uU/mL, normal range: 0.27-4.20 uU/mL), low free T₃ (fT₃) levels (2.87 pmol/L, normal range 3.10-6.70 pmol/L), and normal free T₄ (fT₄) levels (21.9 pmol/L, normal range: 12.00-22.00 pmol/L). Thyroid peroxidase antibodies and thyroglobulin antibodies were high, while TSH receptor antibodies were negative. With these findings, he was additionally diagnosed with Hashimoto thyroiditis. Thyroid ultrasonography confirmed the diagnosis.

In the inpatient unit, the patient was followed by an interdisciplinary team consisting of a child and adolescent psychiatrist, an adolescent medicine specialist, a pediatric endocrinologist, and a dietician with special training and experience in adolescent EDs. During his three-week stay, he gained 4 kg. Despite the weight gain and the improvement in his nutritional status, bradycardia continued (40-50 bpm). Echocardiography findings were normal, and Holter monitoring only revealed sinus bradycardia. Thyroid functions were monitored closely without any medical treatment, along with his vitals. Before discharge, while TSH levels were still low (0.018 uU/mL), fT₃ levels were thought to be relatively high (3.76 pmol/L) considering his metabolic status. The patient was discharged with a weight of 64.7 kg. At his follow-up visit 2 months later, the boy had gained weight and weighed 75.1 kg. Due to the gradual increase noted in his TSH levels (from 8.91 to 28.84 uU/mL), levothyroxine treatment was started. At that time, fT₃ and fT₄ levels were measured as 7.74 and 4.42 pmol/L, respectively. Two months later, it was learned that he had been using levothyroxine in doses three times higher than the recommended dose. Although monitored closely, due to the drug compliance problems and weight changes with severe body image issues, it was hard to maintain the thyroid levels within a stable course. Stabilization occurred after ten months of therapy when he started using a proper medication schedule and succeeded in preserving his target weight. The course of the thyroid function tests is given in Table 1. Bradycardia also improved with the recovery in thyroid hormone levels.

**Discussion**

In the presence of an unexplained weight loss, decrease in appetite, and abnormal eating attitudes, EDs should be considered. However, other medical diseases leading to a similar clinical status such as hyperthyroidism, Addison’s disease, diabetes mellitus, malignancy, inflammatory bowel disease, immunodeficiency, malabsorption, chronic infections,
and collagen vascular diseases, should also be included in the differential diagnosis (6). Although concern about the cause of weight loss is helpful in the differentiation of EDs from other diseases, coexistence of a medical disease and an ED complicates the diagnosis and management of both conditions. Within the group of diseases listed above, hypothyroidism is of particular importance as its laboratory findings as well as its clinical findings such as cold intolerance, constipation, hypothermia, and bradycardia highly resemble those of ED’s.

Hashimoto thyroiditis is a chronic autoimmune inflammation of the thyroid gland and it is the most common cause of acquired hypothyroidism in adolescents (7). The hypothesis that autoimmune mechanisms are involved in the pathogenesis of EDs has become more acceptable in recent years, supported by the results of several studies indicating that autoimmune diseases occur in higher ratios in ED cases (8,9). Hashimoto thyroiditis may exist before or it can develop after the diagnosis of AN. Although patients with Hashimoto thyroiditis generally present at the euthyroid state, Hashimoto thyroiditis either by causing hyper- or hypothyroidism could complicate the management of EDs.

Hypothyroidism caused by Hashimoto thyroiditis may complicate the management of AN by increasing the susceptibility to gain weight, thus inducing the AN patient to eat less. Hashimoto thyroiditis could also disrupt the management of AN by causing hyperthyroidism. The literature contains many reports on hyperthyroidism, mostly due to Graves’ disease, worsening AN either by leading to weight loss itself or by increasing the psychological distress by causing hyperphagia, weight gain, and a fear of losing self-control over eating (10,11,12). In the clinical course of our patient, Hashimoto thyroiditis disrupted the management of AN first by causing hyperthyroidism and then by leading to hypothyroidism. In the presence of AN, treatment of Hashimoto thyroiditis is challenging as well. AN could negatively affect the treatment of Hashimoto thyroiditis by altering the body weight and the metabolic rate, as well as by causing drug non-compliance.

While following patients with AN, because malnutrition could mask the clinical manifestations, the diagnosis of hyper- or hypothyroidism might be overlooked. Therefore, further analysis is needed when the major complaint does not improve with sufficient weight gain or when the levels of fT3, fT4, and TSH are incompatible with the body weight and nutritional status. Initially, our case was thought to have hyperthyroidism as the autoantibodies were positive, TSH level was lower than expected, and fT4 level was at the upper limits. However, during follow-up and within a short period of time, TSH suppression disappeared, T4 level started to decrease, and findings consistent with hypothyroidism became evident. Bradycardia being resistant to weight gain but improving after levothyroxine treatment was probably related to hypothyroidism as well.

Differentiating between primary thyroid diseases and low T3 syndrome is important in the achievement of best treatment outcome. Levothyroxine treatment is not recommended in low T3 syndrome, because it may cause weight loss, which is often mediated by loss of muscle mass (13). Also, thyroid hormone therapy, by leading to a decrease in weight, could obstruct the evaluation of patient’s response to treatment or could lead to the deterioration of symptoms (14,15). On the other hand, levothyroxine treatment could be given when hypothyroidism due to a primary thyroid disease accompanies AN. This raises the question of when to start levothyroxine in the coexistence of these two conditions. For our patient, thyroid functions tests were monitored closely during his hospital admission, and levothyroxine was initiated two months after discharge when he had gained enough weight and had become metabolically stable. Another problem is that, depending on the beliefs and attitudes of patients with AN, they could either reject using levothyroxine as it may lead to hyperphagia and weight gain or misuse it to lose weight (7,16). In addition, weight fluctuations may complicate the dose adjustment of thyroid hormone therapy in these patients. Our patient’s thyroid hormone levels could only be stabilized after he began to take the recommended dosage of levothyroxine and preserved his target weight.

Review of the literature for the association of Hashimoto thyroiditis with EDs revealed only one recently published case report of a 16-year-old girl with a 4-year history of AN whose TSH levels had increased in response to weight gain and shown a decrease with weight loss. This unexpected pattern of TSH and markedly elevated levels of antithyroid peroxidase antibodies suggested Hashimoto thyroiditis (17). The association between body weight and TSH levels observed in this case report was also present in our patient. With weight restoration, an elevation in TSH

| Table 1. Thyroid function test results of the patient (initial values and subsequent monthly results) |
|-------------------------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| TSH (uIU/mL)                                   | Initial| 1st    | 2nd    | 4th    | 5th    | 6th    | 7th    | 10th   | 12th   | 18th   |
| 0.025                                          | 8.91   | 28.84  | 0.03   | 3.33   | 6.90   | 0.03   | 3.28   | 5.78   | 6.26   |        |
| T3 (pmol/L)                                    | 2.87   | 3.57   | 4.42   | 4.50   | 2.80   | 3.50   | 3.42   | 3.56   | 3.56   | 4.13   |
| T4 (pmol/L)                                    | 21.19  | 7.79   | 7.74   | 15.38  | 7.49   | 8.68   | 14.31  | 9.96   | 9.29   | 8.77   |

Normal ranges for initial values of thyroid-stimulating hormone (TSH): 0.27-4.20 uIU/mL, free triiodothyronine (T3): 3.10-6.70 pmol/L, free thyroxin (T4): 12.00-22.00 pmol/L.

Normal ranges for subsequent values of TSH: 0.34-5.60 uIU/mL, free T3: 3.80-6.00 pmol/L, free T4: 7.86-14.41 pmol/L.
levels occurred and levothyroxine treatment was started after TSH levels continued to rise with increasing weight similar to the case cited above. However, since levothyroxine had to be started in an earlier phase due to the hormonal status, the pattern of weight loss associated with decreases in TSH was not observed in our patient. Also, unlike the cited case, our patient was diagnosed with AN and Hashimoto thyroiditis at the same time. Moreover, initial tests of our patient being consistent with hyperthyroidism and misusage of levothyroxine created additional challenges during the follow-up.

Although Hashimoto thyroiditis is accepted as one of the most common autoimmune endocrine disorders, its effect on EDs seems to be lacking in the literature. This case of AN in conjunction with Hashimoto thyroiditis is informative as it highlights the challenges faced during the diagnosis and treatment of Hashimoto thyroiditis in the presence of AN and attracts attention to the effect of this coexistence on the patient.

**Ethics**

Informed Consent: It was taken.

Peer-review: External peer-reviewed.

**Authorship Contributions**

Concept: Nuray Kanbur, Sinem Akgül, Ayfer Alikaşifoğlu,
Design: Melis Pehlivantürk Kızılkan, Nuray Kanbur, Sinem Akgül, Ayfer Alikaşifoğlu, Data Collection or Processing: Melis Pehlivantürk Kızılkan, Analysis or Interpretation: Melis Pehlivantürk Kızılkan, Nuray Kanbur, Literature Search: Melis Pehlivantürk Kızılkan, Writing: Melis Pehlivantürk Kızılkan.

Financial Disclosure: The authors declared that this study has received no financial support.

**References**

1. Miyai K, Yamamoto T, Azukizawa M, Ishibashi K, Kumahara Y. Serum thyroid hormones and thyrotropin in anorexia nervosa. J Clin Endocrinol Metab 1975;40:334-338.
2. Fisher M, Golden NH, Katzman DK, Kreipe RE, Rees J, Schebendach J, Sigman G, Ammerman S, Hoberman HM. Eating disorders in adolescents: a background paper. J Adolesc Health 1995;16:420-437.
3. Usdan LS, Khaodhiar L, Aposian CM. The endocrinopathies of anorexia nervosa. Endocr Pract 2008;14:1055-1063.
4. Kiyohara K, Tamai H, Takaichi Y, Nakagawa T, Kumagai LF. Decreased thyroid triiodothyronine secretion in patients with anorexia nervosa: influence of weight recovery. Am J Clin Nutr 1989;50:767-772.
5. Misra M, Klibanski A. Neuroendocrine consequences of anorexia nervosa in adolescents. Endocr Dev 2010;17:197-214. Epub 2009 Nov 24.
6. Forman SF. The role of the primary care provider in the diagnosis and management of eating disorders: Anorexia nervosa and bulimia nervosa. Under the direction of. In: Ernans SJ, Woods ER, Keenan PM (eds). Medicine Pcia, Boston, Massachusetts 2001.
7. Catrergi P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev 2014;13:391-397. Epub 2014 Jan 13.
8. Raevuori A, Haukka J, Vaarala O, Suvisaari J, M. Giessler M, Granger M, Linna MS, Suokas JT. The increased risk for autoimmune diseases in patients with eating disorders. PLoS One 2014;9:104848.
9. Acres MJ, Heath JJ, Morris JA. Anorexia nervosa, autoimmunity and the hygiene hypothesis. Med Hypotheses 2012;78:772-775. Epub 2012 Mar 31.
10. Birmingham CL, Gritzner S, Guitierrez E. Hyperthyroidism in anorexia nervosa: a case report and review of the literature. Int J Eat Disord 2006;39:619-620.
11. Raymond D, Asfaha EA, Babiker A, Jaffa T. Hyperthyroidism during refeeding in anorexia nervosa. Int J Eat Disord 2012;45:460-462. Epub 2011 Oct 18.
12. Fonseca V, Wakeling A, Havard CW. Hyperthyroidism and eating disorders. BMJ 1990;301:322-323.
13. Warren MP. Endocrine manifestations of eating disorders. J Clin Endocrinol Metab 2011;96:333-343.
14. Laurberg P, Knudsen N, Andersen S, Carle A, Pedersen IB, Karmisholt J. Thyroid function and obesity. Eur Thyroid J 2012;1:159-167. Epub 2012 Sep 22.
15. Pearce EN. Thyroid hormone and obesity. Curr Opin Endocrinol Diabetes Obes 2012;19:408-413.
16. Woodside DB, Walfish P, Kaplan AS, Kennedy SH. Graves' disease in a woman with thyroid hormone abuse, bulimia nervosa and a history of anorexia nervosa. Int J Eat Disord 1991;10:111-115.
17. Smalls-Manley A, Steinglass J, Primack M, Clark-Hamilton J, Bongovi M. Hypothyroidism due to Hashimoto's thyroiditis masked by anorexia nervosa. Int J Eat Disord 2015;48:932-935. Epub 2015 May 6.